| 序号 | 专利名 | 申请号 | 申请日 | 公开（公告）号 | 公开（公告）日 | 发明人 |
|---|---|---|---|---|---|---|
| 121 | PREPARAÇÃO DE PRODUTOS DE CEREAIS APROPRIADOS PARA DOENTES CELÍACOS ATRAVÉS DA FORMAÇÃO DE ESTRUTURAS SUPRAMOLECULARES DE PROTEÍNAS E QUITOSANA | PCT/IB2017/054181 | 2017-07-11 | WO2018011714A1 | 2018-01-18 | FERREIRA MILHEIRO NUNES, Fernando Hermínio; IGREJAS, Gilberto; SILVA FERREIRA RIBEIRO, José Miguel |
A presente invenção é referente a um processo de destoxificação da farinha de trigo (Triticum spp.) e glúten através da formação de estruturas supramoleculares com a quitosana. A invenção refere-se também à respetiva farinha e glúten destoxificados em que são obtidos valores de redução de epitopos tóxicos para os doentes celíacos de 65 e 88% quando comparados com a farinha e glúten não modificados ou originais, respetivamente. Adicionalmente diz ainda respeito à utilização do processo de destoxificação noutros cereais e respetivos produtos, nomeadamente em outras gramíneas (Poaceae), subfamília Pooideae, principalmente das espécies da tribo Triticeae como a cevada (Hordeum spp.), o centeio (Secale spp.), o triticale (x Triticosecale) e da tribo Aveneae como a aveia (Avena spp.), bem como os seus produtos germinados. |
||||||
| 122 | A USE OF THE MIXTURE OF A SALT AND SUGAR IN THE MANUFACTURE OF A MEDICAMENT EMPLOYED FOR TREATING LAX VEGINA SYNDROME OR COLPOXEROSIS DISEASE IN A MAMMAL | PCT/KR2014/008180 | 2014-09-02 | WO2015050324A1 | 2015-04-09 | CHOI, Won Seog; KWON, Dong-yeul |
The present invention relates to a use of the mixture of a salt and sugar in the manufacture of a medicament employed for treating lax vegina syndrome or colpoxerosis disease in a mammal. As described in the present invention, through various tests, for example, vaginal smooth muscle contractility test using by New Zealand White Rabbit; (Experimental example 1); the effect on the vagina contractility in volunteers by using perinometer (Experimental example 2); and the effect on the colpoxerosis disease in volunteers (Experimental example 3), the inventive combination showed improving effect on the contractility of vagina tissue and colpoxerosis disease. Accordingly, the inventive combination can be useful in treating or preventing lax vegina syndrome or colpoxerosis disease. |
||||||
| 123 | Methods and Apparatus for Detection of Gluten Sensitivity, and its Differentiation from Celiac Disease | US15258949 | 2016-09-07 | US20160377629A1 | 2016-12-29 | Aristo Vojdani |
| Antibodies are used as biomarkers to assist in distinguishing gluten immune reactivity and sensitivity, silent celiac disease, Crohn's disease and other gut-related pathologies from classical celiac disease. In one class of embodiments, sera, saliva or other samples from a human or other animal are tested for antibodies to (a) a wheat antigen; (b) a gliadin antigen; and (c) one or more of a wheat germ agglutinin, a gluteomorphin, a glutenin, a deamidated glutenin, a prodynorphin, and a dynorphin. Test results are considered particularly interesting where the wheat antigen and the gliadin antigen are both selected from the group consisting of native and deamidated forms of α-gliadin 33-mer, α-gliadin-17-mer, γ-gliadin-15-mer, ω-gliadin-17-mer, and glutenin 21-mer. Test plates and kits can advantageously test for antibodies to at least three, five, seven or all of mixed wheat antigens, α-gliadin, γ-gliadin, ω-gliadin, glutenin, α-glutenin, wheat germ agglutinin, gluteomorphin, prodynorphins, transglutaminase-2, transglutaminase-3, transglutaminase-6, and gliadin-bound transglutaminase. | ||||||
| 124 | Methods to predict risk for celiac disease by detecting anti-flagellin antibody levels | US12392997 | 2009-02-25 | US08409819B1 | 2013-04-02 | Derren M. Barken |
| The present invention provides methods, assays, and kits for predicting or stratifying the risk of celiac disease (CD) based upon HLA-DQ genotype and/or anti-flagellin antibody levels. Such risk prediction or stratification can provide benefits to family members of CD patients, to a subset of patients who are being evaluated clinically for CD, and to researchers, who can utilize this strategy to establish inclusion criteria for participation in research studies investigating potential preventive interventions. | ||||||
| 125 | Compounds for the selective treatment of the intestinal immuno-inflammatory component of the celiac disease | US12810159 | 2008-12-23 | US08153693B2 | 2012-04-10 | Sergio Baroni; Salvatore Bellinvia |
| The present invention relates to amino-salicylic-aminophenyl compounds for use in the treatment of the inflammatory component of celiac disease. These compounds act by blocking the cytokines released in celiac disease and are specifically useful in the treatment of refractory cases. | ||||||
| 126 | PHARMACEUTICAL COMPOSITIONS COMPRISING POLYMERIC BINDERS WITH NON-HYDROLYSABLE COVALENT BONDS AND THEIR USE IN TREATING CELIAC DISEASE | EP06790907 | 2006-10-27 | EP1948201A4 | 2013-12-25 | LEROUX JEAN-CHRISTOPHE; NASSER EDDINE MOHAMAD |
| A pharmaceutical composition comprising a polymeric binder including a high molecular weight synthetic polymer having a backbone constituted of non hydrolysable covalent bonds, said polymer being able to form electrostatic bonds at a pH lower than the isoelectric point of gluten and peptides derived from the degradation of gluten, and being able to bind to gluten or peptides derived from the degradation of gluten in the gastrointestinal tract, and a pharmaceutically acceptable carrier. Methods of using the polymeric binder for binding gluten or a peptide derived from the degradation of gluten, for decreasing the degradation of gluten into toxic peptides or for decreasing interaction of gluten or peptides derived from the degradation of gluten with the gastrointestinal mucosa. | ||||||
| 127 | PHARMACEUTICAL COMPOSITIONS COMPRISING POLYMERIC BINDERS WITH NON-HYDROLYSABLE COVALENT BONDS AND THEIR USE IN TREATING CELIAC DISEASE | EP06790907.7 | 2006-10-27 | EP1948201A1 | 2008-07-30 | LEROUX, Jean-Christophe; NASSER EDDINE, Mohamad |
| A pharmaceutical composition comprising a polymeric binder including a high molecular weight synthetic polymer having a backbone constituted of non hydrolysable covalent bonds, said polymer being able to form electrostatic bonds at a pH lower than the isoelectric point of gluten and peptides derived from the degradation of gluten, and being able to bind to gluten or peptides derived from the degradation of gluten in the gastrointestinal tract, and a pharmaceutically acceptable carrier. Methods of using the polymeric binder for binding gluten or a peptide derived from the degradation of gluten, for decreasing the degradation of gluten into toxic peptides or for decreasing interaction of gluten or peptides derived from the degradation of gluten with the gastrointestinal mucosa. | ||||||
| 128 | METHOD FOR DETERMINING IF A SUBJECT HAS AN INCREASED LIKELIHOOD OF HIGH GRADE DYSPLASIA OR ESOPHAGAL ADENOCARCINOMA | EP13731426.6 | 2013-05-17 | EP2850208B1 | 2017-07-19 | DI PIETRO, Massimiliano; FITZGERALD, Rebecca; LIU, Xinxue |
| 129 | Compounds for the selective treatment of the intestinal immuno-inflammatory component of the celiac disease | EP10188940.0 | 2008-12-23 | EP2279733A3 | 2011-03-23 | Baroni, Sergio; Bellinvia, Salvatore |
In one aspect, the present invention relates to amino-salicylic - aminophenylpropionic compounds for the use in the treatment of the inflammatory component of the celiac disease. These compounds act by blocking the cytokines released in the celiac disease and are specifically useful in the treatment of cases refractory to the diet, in dietary errors and in the reduction of the celiac disease remission time. |
||||||
| 130 | Pharmaceutical compositions comprising polymeric binders with non-hydrolysable their use in treating celiac disease | US12093423 | 2006-10-27 | US08883133B2 | 2014-11-11 | Jean-Christophe Leroux; Mohamad Nasser Eddine |
| A pharmaceutical composition comprising a polymeric binder including a high molecular weight synthetic polymer having a backbone constituted of non hydrolysable covalent bonds, said polymer being able to form electrostatic bonds at a pH lower than the isoelectric point of gluten and peptides derived from the degradation of gluten, and being able to bind to gluten or peptides derived from the degradation of gluten in the gastrointestinal tract, and a pharmaceutically acceptable carrier. Methods of using the polymeric binder for binding gluten or a peptide derived from the degradation of gluten, for decreasing the degradation of gluten into toxic peptides or for decreasing interaction of gluten or peptides derived from the degradation of gluten with the gastrointestinal mucosa. | ||||||
| 131 | Novel epitopes for celiac disease and autoimmune diseases, methods for detecting those and novel non-antigenic food compounds | US10503575 | 2003-02-04 | US20050244823A1 | 2005-11-03 | Jan Drijfhout; Petrus van Veelen; Frits Koning |
| The invention describes the patterns of deamidation in gluten, and it is found that this is highly dependent on the spacing between the glutamine and proline residues. This knowledge can be used to predict novel T cell stimulatory gluten peptides. Several newly defined peptides and epitopes are provided. Also, the finding can explain the formation of neo-epitopes in autoimmune diseases such as RA (rheumatoid arthritis), MS (multiple sclerosis), SLE (systemic lupus erythomatosus), SS (Sjogren syndrome) and DB (diabetes). Several neo-epitopes and the peptides that are substrate for deamidation are provided. Further, the inventions provides for methods for detecting these peptides and epitopes and methods for making food more suitable for celiac disease patients. | ||||||
| 132 | 治疗小麦敏感性的HMO混合物 | CN201880088048.9 | 2018-11-30 | CN111698994A | 2020-09-22 | L·K·比格斯奈斯; B·麦康奈尔 |
| 本发明涉及人乳寡糖(HMO)、包含HMO的合成组合物用于人的非乳糜泻小麦和/或麸质敏感性的治疗、二级预防和/或诱导耐受性以及其方法。 | ||||||
| 133 | 谷蛋白引起的自身免疫性疾病的诊断 | CN201080024345.0 | 2010-04-01 | CN102834720B | 2015-06-17 | I·科尔波瑙伊-绍博; L·费许什; P·鲍戈斯; E·彻斯; R·基拉伊; Z·西蒙-韦切伊; M·马基 |
| 本发明涉及通过利用存在于谷氨酰胺转移酶家族蛋白质上的主要乳糜泻抗原表位的结合分析对谷蛋白引起的自身免疫性疾病的选择性诊断。 | ||||||
| 134 | 治疗炎症性和自身免疫性疾病的组合物和方法 | CN201980072748.3 | 2019-10-31 | CN113329771A | 2021-08-31 | K·谢卢拜 |
| 本发明涉及治疗病症如乳糜泻的方法，所述方法通过施用单独或与另外的剂组合的抗CD3抗体进行。 | ||||||
| 135 | 谷蛋白引起的自身免疫性疾病的诊断 | CN201080024345.0 | 2010-04-01 | CN102834720A | 2012-12-19 | I·科尔波瑙伊-绍博; L·费许什; P·鲍戈斯; E·彻斯; R·基拉伊; Z·西蒙-韦切伊; M·马基 |
| 本发明涉及通过利用存在于谷氨酰胺转移酶家族蛋白质上的主要乳糜泻抗原表位的结合分析对谷蛋白引起的自身免疫性疾病的选择性诊断。 | ||||||
| 136 | 加波沙朵在治疗胃肠道紊乱和哮喘中的用途 | CN201980069028.1 | 2019-08-22 | CN112888437A | 2021-06-01 | 马修·杜林 |
| 提供了使用加波沙朵或其药学上可接受的盐治疗肠易激综合征、克罗恩病、乳糜泻、溃疡性结肠炎、显微镜下结肠炎和哮喘。还提供了可以被用于改善肠易激综合征、克罗恩病、乳糜泻、溃疡性结肠炎、显微镜下结肠炎或哮喘中的一种或更多种症状的治疗性组合物。 | ||||||
| 137 | 蛋白酶针对谷蛋白不耐受的用途 | CN201180008536.2 | 2011-02-02 | CN102858795A | 2013-01-02 | 詹姆斯·F·乔利; 井户宏树; 松原宽敬; 高桥哲也; 西尾享一 |
| 本发明的技术涉及酶组合物。所述酶组合物可以用来治疗谷蛋白不耐受性受试者，包括患有非乳糜泻谷蛋白不耐受和/或非乳糜泻谷蛋白敏感的受试者。所述酶组合物也可以用来减少某些个体中的谷蛋白暴露。例如，该酶组合物也可以用作预防药以减少对谷蛋白寡肽的暴露。 | ||||||
| 138 | 对麸质不耐受以及相关病症的治疗 | CN201380070689.9 | 2013-11-20 | CN105007934B | 2019-02-05 | 戴维·施里默; 马尔什·雷伊 |
| 本文提供一种包含猪笼草蛋白酶或其衍生物的组合物、食品以及使用猪笼草蛋白酶或其衍生物调节麸质不耐受以及诸如乳糜泻之类的相关病症的方法。 | ||||||
| 139 | 对麸质不耐受以及相关病症的治疗 | CN201380070689.9 | 2013-11-20 | CN105007934A | 2015-10-28 | 戴维·施里默; 马尔什·雷伊 |
| 本文提供一种包含猪笼草蛋白酶或其衍生物的组合物、食品以及使用猪笼草蛋白酶或其衍生物调节麸质不耐受以及诸如乳糜泻之类的相关病症的方法。 | ||||||
| 140 | 特异性地结合人IL-15的抗体及其用途 | CN201780079926.6 | 2017-12-21 | CN110234349B | 2024-03-22 | 大卫·约瑟·西蒙·莱恩; 马修·波拉德; 安东尼·杰拉德·道尔; 林恩·多萝西·普尔顿; 亚当·威廉·克拉克 |
| 提供了特异性地结合IL‑15以及IL‑15与IL‑15受体α的复合物的重组抗体。所述抗体抑制免疫细胞增殖，并且能够用于治疗IL‑15失调的任何自身免疫性或炎性疾病或疾患，包括乳糜泻。 | ||||||
QQ群二维码
意见反馈
意见反馈